Search alternatives:
teer decrease » greater decrease (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
teer decrease » greater decrease (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
19861
Structural and Co-conformational Effects of Alkyne-Derived Subunits in Charged Donor−Acceptor [2]Catenanes
Published 2007“…The barriers for the three processes were found to be successively 14.4, 14.5−17.5, and 13.1−15.8 kcal mol<sup>-1</sup>. Within the limitations of the small dataset investigated, emergent trends in the barrier heights can be recognized: the values decrease with the increasing size of the π-electron-donating macrocycle and tend to be lower in the sterically less encumbered series of [2]catenanes containing the 1,3-butadiyne moiety.…”
-
19862
Effect of Substituents on the Water Oxidation Activity of [Ru<sup>II</sup>(terpy)(phen)Cl]<sup>+</sup> Procatalysts
Published 2014“…A series of [Ru<sup>II</sup>(terpy-R)(phen-X)Cl]PF<sub>6</sub> complexes was designed where terpy-R is the tridentate 4′-(4-methylmercaptophenyl)-2,2′:6′2″-terpyridine ligand MeMPTP and phen-X is a substituted phenanthroline with hydro (<b>1</b>), 5-nitro (<b>2</b>), 5,6-dimethyl (<b>3</b>), and 3,4,7,8-tetramethyl (<b>4</b>). …”
-
19863
Effect of Substituents on the Water Oxidation Activity of [Ru<sup>II</sup>(terpy)(phen)Cl]<sup>+</sup> Procatalysts
Published 2014“…A series of [Ru<sup>II</sup>(terpy-R)(phen-X)Cl]PF<sub>6</sub> complexes was designed where terpy-R is the tridentate 4′-(4-methylmercaptophenyl)-2,2′:6′2″-terpyridine ligand MeMPTP and phen-X is a substituted phenanthroline with hydro (<b>1</b>), 5-nitro (<b>2</b>), 5,6-dimethyl (<b>3</b>), and 3,4,7,8-tetramethyl (<b>4</b>). …”
-
19864
-
19865
-
19866
-
19867
-
19868
-
19869
-
19870
Spectral-domain optical coherence tomography (SD-OCT) images taken from a 72-year-old female patient with neovascular age-related macular degeneration (nAMD) who received ranibizum...
Published 2025“…However, the patient’s treatment was interrupted for 3.5 months because of the COVID-19 lockdown. When the patient returned for treatment, the BCVA had decreased to 0.73 (logMAR); the corresponding OCT image taken at V1 (C) shows subretinal hemorrhage, IRF and SRF. …”
-
19871
Data_Sheet_1_Growth of freshwater cyanobacterium Aphanizomenon sp. ULC602 in different growing and nutrient conditions.docx
Published 2023“…Moreover, a decrease in Chlo-a biomass was observed under sulfur deficiency. …”
-
19872
-
19873
-
19874
Table 1_Eculizumab is efficacious and safe in pediatric patients with various forms of hemolytic uremic syndrome: a retrospective clinical experience of a tertiary center.docx
Published 2025“…</p>Results<p>Twenty-four pediatric patients (median age 5.8 years) were included: 13 with aHUS, 5 with STEC-HUS, and 6 with TA-TMA. …”
-
19875
Table_1_Effectiveness, Healthcare Resource Utilization and Adherence to Subcutaneous Interferon Beta-1a According to Age in Patients With Multiple Sclerosis: A Cohort Study Using a...
Published 2021“…</p><p>Results: Of the 5,340 patients included in the analysis, there was a high proportion of patients free from relapse across all age groups (range: 94.1–95.4%), with a numerical decrease in the number of MRI performed by age (mean: 0.25, 18–30 years; 0.20, 31–40 years; 0.16, 41–50 years; 0.14, ≥51 years). …”
-
19876
Table_1_Effectiveness, Healthcare Resource Utilization and Adherence to Subcutaneous Interferon Beta-1a According to Age in Patients With Multiple Sclerosis: A Cohort Study Using a...
Published 2021“…</p><p>Results: Of the 5,340 patients included in the analysis, there was a high proportion of patients free from relapse across all age groups (range: 94.1–95.4%), with a numerical decrease in the number of MRI performed by age (mean: 0.25, 18–30 years; 0.20, 31–40 years; 0.16, 41–50 years; 0.14, ≥51 years). …”
-
19877
-
19878
-
19879
-
19880